Astec LifeSciences saw improved financial results.

Total income rose to ₹453.22 Cr, achieving EBITDA break-even for the year from a prior loss.

Net loss significantly reduced.

Domestic sales jumped 40.6%, exports grew 6.7%. CDMO now drives 52% of sales.

A Rights Issue successfully raised ₹249.35 Cr.

New Chairperson and Executive Director appointments were announced.